Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancers
1994

Cyclic AMP-Binding Proteins in Ovarian Cancer

Sample size: 50 publication Evidence: moderate

Author Information

Author(s): A.D. Ramage, D.J. Bums, W.R. Miller

Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh, UK

Hypothesis

The study aims to characterize an assay for cAMP-binding proteins in ovarian cancer and measure their levels to develop a potential prognostic indicator.

Conclusion

High levels of cAMP-binding proteins in ovarian cancer may indicate poor prognosis.

Supporting Evidence

  • All tumors showed cAMP binding, but levels varied greatly between individual tumors, from 267 to 12,037 fmol per mg of cytosol protein.
  • The mean value of cAMP binding was 4248 fmol mg-1.
  • Dissociation constants for binding ranged between 0.4 and 5.9 x 10-8 M.
  • Proteins with molecular weights of 52, 48, 43, 39, and 37 kDa were identified in the cytosols.

Takeaway

This study looked at proteins in ovarian cancer that might help doctors predict how bad the cancer is. They found that more of these proteins could mean a worse outcome for patients.

Methodology

The study involved measuring cAMP-binding proteins in cytosols from 50 ovarian tumors using a specific assay.

Limitations

The significance of the findings awaits clinical follow-up of the patients.

Participant Demographics

Tumor samples were obtained from 50 patients with histologically proven ovarian cancer.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication